142 related articles for article (PubMed ID: 9654335)
21. Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters.
Kilbourn MR; Frey KA; Vander Borght T; Sherman PS
Nucl Med Biol; 1996 May; 23(4):467-71. PubMed ID: 8832701
[TBL] [Abstract][Full Text] [Related]
22. Increased platelet vesicular monoamine transporter density in adult schizophrenia patients.
Zucker M; Valevski A; Weizman A; Rehavi M
Eur Neuropsychopharmacol; 2002 Aug; 12(4):343-7. PubMed ID: 12126874
[TBL] [Abstract][Full Text] [Related]
23. High-efficiency expression and characterization of the synaptic-vesicle monoamine transporter from baculovirus-infected insect cells.
Sievert MK; Thiriot DS; Edwards RH; Ruoho AE
Biochem J; 1998 Mar; 330 ( Pt 2)(Pt 2):959-66. PubMed ID: 9480916
[TBL] [Abstract][Full Text] [Related]
24. Changes in vesicular monoamine transporter (VMAT2) and synaptophysin in rat Substantia nigra and prefrontal cortex induced by psychotropic drugs.
Zucker M; Weizman A; Harel D; Rehavi M
Neuropsychobiology; 2001; 44(4):187-91. PubMed ID: 11702019
[TBL] [Abstract][Full Text] [Related]
25. Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains.
Kilbourn M; Frey K
Eur J Pharmacol; 1996 Jun; 307(2):227-32. PubMed ID: 8832225
[TBL] [Abstract][Full Text] [Related]
26. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine.
Frey K; Kilbourn M; Robinson T
Eur J Pharmacol; 1997 Sep; 334(2-3):273-9. PubMed ID: 9369358
[TBL] [Abstract][Full Text] [Related]
27. Effects of nerve growth factor on dihydrotetrabenazine binding to PC12 cells.
Adamson CR; Emley TE; Herbig LJ; Near JA
Neurochem Int; 1997; 30(4-5):411-5. PubMed ID: 9106255
[TBL] [Abstract][Full Text] [Related]
28. Decreased platelet vesicular monoamine transporter density in habitual smokers.
Schwartz K; Weizman A; Rehavi M
Eur Neuropsychopharmacol; 2005 Mar; 15(2):235-8. PubMed ID: 15695071
[TBL] [Abstract][Full Text] [Related]
29. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine.
Koeppe RA; Frey KA; Kuhl DE; Kilbourn MR
J Cereb Blood Flow Metab; 1999 Dec; 19(12):1376-84. PubMed ID: 10598942
[TBL] [Abstract][Full Text] [Related]
30. Synthesis of a [11C]methoxy derivative of alpha-dihydrotetrabenazine: a radioligand for studying the vesicular monoamine transporter.
DaSilva JN; Kilbourn MR; Mangner TJ
Appl Radiat Isot; 1993 Dec; 44(12):1487-9. PubMed ID: 7903060
[TBL] [Abstract][Full Text] [Related]
31. Autoradiographic distribution of the eye monoaminergic synaptic vesicles.
Denis P; Nordmann JP; Scherman D; Saraux H; Rostène W
Ophthalmic Res; 1994; 26(4):232-9. PubMed ID: 7808734
[TBL] [Abstract][Full Text] [Related]
32. Vesicular monoamine transporter 2 expression in enteric neurons and enterochromaffin-like cells of the rat.
De Giorgio R; Su D; Peter D; Edwards RH; Brecha NC; Sternini C
Neurosci Lett; 1996 Oct; 217(2-3):77-80. PubMed ID: 8916076
[TBL] [Abstract][Full Text] [Related]
33. Reserpine- and tetrabenazine-sensitive transport of (3)H-histamine by the neuronal isoform of the vesicular monoamine transporter.
Erickson JD; Eiden LE; Schafer MK; Weihe E
J Mol Neurosci; 1995; 6(4):277-87. PubMed ID: 8860238
[TBL] [Abstract][Full Text] [Related]
34. Transient uptake and storage of serotonin in developing thalamic neurons.
Lebrand C; Cases O; Adelbrecht C; Doye A; Alvarez C; El Mestikawy S; Seif I; Gaspar P
Neuron; 1996 Nov; 17(5):823-35. PubMed ID: 8938116
[TBL] [Abstract][Full Text] [Related]
35. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments.
Vander Borght T; Kilbourn M; Desmond T; Kuhl D; Frey K
Eur J Pharmacol; 1995 Dec; 294(2-3):577-83. PubMed ID: 8750721
[TBL] [Abstract][Full Text] [Related]
36. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
Suzuki M; Desmond TJ; Albin RL; Frey KA
Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
[TBL] [Abstract][Full Text] [Related]
37. Vesicular amine transporter expression and isoform selection in developing brain, peripheral nervous system and gut.
Schütz B; Schäfer MK; Eiden LE; Weihe E
Brain Res Dev Brain Res; 1998 Mar; 106(1-2):181-204. PubMed ID: 9555003
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo studies of benzisoquinoline ligands for the brain synaptic vesicle monoamine transporter.
Lee LC; Vander Borght T; Sherman PS; Frey KA; Kilbourn MR
J Med Chem; 1996 Jan; 39(1):191-6. PubMed ID: 8568807
[TBL] [Abstract][Full Text] [Related]
39. Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2. II. Expression in neural crest derivatives and their target sites in the rat.
Hansson SR; Mezey E; Hoffman BJ
Brain Res Dev Brain Res; 1998 Sep; 110(1):159-74. PubMed ID: 9733958
[TBL] [Abstract][Full Text] [Related]
40. High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates.
Zubieta JK; Huguelet P; Ohl LE; Koeppe RA; Kilbourn MR; Carr JM; Giordani BJ; Frey KA
Am J Psychiatry; 2000 Oct; 157(10):1619-28. PubMed ID: 11007716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
